Literature DB >> 22951101

Thiazide diuretics in advanced chronic kidney disease.

Rajiv Agarwal1, Arjun D Sinha.   

Abstract

Chronic kidney disease (CKD) is prevalent in 3%-4% of the adult population in the United States, and the vast majority of these people are hypertensive. Compared with those with essential hypertension, hypertension in CKD remains poorly controlled despite the use of multiple antihypertensive drugs. Hypervolemia is thought to be a major cause of hypertension, and diuretics are useful to improve blood pressure control in CKD. Non-osmotic storage of sodium in the skin and muscle may be a novel mechanism by which sodium may modulate hypertension; further work is need to study this novel phenomenon with diuretics. Among people with stage 4 CKD, loop diuretics are recommended over thiazides. Thiazide diuretics are deemed ineffective in people with stage 4 CKD. Review of the literature suggests that thiazides may be useful even among people with advanced CKD. They cause a negative sodium balance, increasing sodium excretion by 10%-15% and weight loss by 1-2 kg in observational studies. Observational data show improvement in seated clinic blood pressure of about 10-15 mm Hg systolic and 5-10 mm Hg diastolic, whereas randomized trials show about 15 mm Hg improvement in mean arterial pressure. Volume depletion, hyponatremia, hypokalemia, hypercalcemia, and acute kidney injury are adverse effects that should be closely monitored. Our review suggests that adequately powered randomized trials are needed before the use of thiazide diuretics can be firmly recommended in those with advanced CKD. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951101     DOI: 10.1016/j.jash.2012.07.004

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  21 in total

Review 1.  Tolerability of Antihypertensive Medications in Older Adults.

Authors:  Thiruvinvamalai S Dharmarajan; Lekshmi Dharmarajan
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

2.  Counterpoint: the treatment decision design.

Authors:  M Alan Brookhart
Journal:  Am J Epidemiol       Date:  2015-10-26       Impact factor: 4.897

Review 3.  Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.

Authors:  Samuel J Mann; Michael E Ernst
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 4.  A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative.

Authors:  Steven Hsu; Van-Khue Ton; M Dominique Ashen; Seth S Martin; Ty J Gluckman; Payal Kohli; Stephen D Sisson; Roger S Blumenthal; Michael J Blaha
Journal:  Clin Cardiol       Date:  2013-05-13       Impact factor: 2.882

5.  Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.

Authors:  Rajiv Agarwal; Andrew E Cramer; Mary Balmes-Fenwick; Arjun D Sinha; Fangqian Ouyang; Wanzhu Tu
Journal:  Am J Nephrol       Date:  2020-07-14       Impact factor: 3.754

Review 6.  Thiazide Diuretics in Chronic Kidney Disease.

Authors:  Arjun D Sinha; Rajiv Agarwal
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

7.  Outcomes of diuretic use in pre-dialysis CKD patients with moderate renal deterioration attending tertiary care referral center.

Authors:  Yusra Habib Khan; Azmi Sarriff; Azreen Syazril Adnan; Amer Hayat Khan; Tauqeer Hussain Mallhi
Journal:  Clin Exp Nephrol       Date:  2017-03-07       Impact factor: 2.801

Review 8.  Hypertension in Chronic Kidney Disease - Role of Arterial Calcification and Impact on Treatment.

Authors:  Olivier Phan; Michel Burnier; Grégoire Wuerzner
Journal:  Eur Cardiol       Date:  2014-12

Review 9.  Diuretics in the treatment of hypertension.

Authors:  Douglas L Blowey
Journal:  Pediatr Nephrol       Date:  2016-03-16       Impact factor: 3.714

10.  Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D.

Authors:  Paulette D Chandler; Jamil B Scott; Bettina F Drake; Kimmie Ng; John P Forman; Andrew T Chan; Gary G Bennett; Bruce W Hollis; Edward L Giovannucci; Karen M Emmons; Charles S Fuchs
Journal:  Am J Med       Date:  2014-03-20       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.